Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455

Aptevo Therapeutics Inc.

2025-Q2 EPS reported -$30.84 vs consensus -$1527.55 ▲ beat (+98.0%)

Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.
Raised $15.9M in Q2; extended cash runway into late Q4 2025; secured up to $25M equity line.
Introduced APVO455, a Nectin-4 x CD3 bispecific for bladder, breast, NSCLC, head & neck cancers.
Mipletamig achieved 85% remission rate (11/13) in frontline AML; no CRS reported.
Shares outstanding grew to 3,224,156 vs 72,922 at Dec 31, 2024 due to equity raises.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.